Device Trial Radar · NCT04177914
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
165
Actual
Start
Jul 21, 2020
Primary completion
May 30, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- University of UtahAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Alabama at Birmingham; University of British Columbia; University of Pittsburgh; The Hospital for Sick Children; Seattle Children's Hospital; Vanderbilt University Medical Center; Washington University School of Medicine; Nationwide Children's Hospital; Johns Hopkins University; University of Calgary; University of Colorado, Denver; Children's Hospital Los Angeles; National Institutes of Health (NIH); Hydrocephalus Association; Penn State University; National Institute of Neurological Disorders and Stroke (NINDS); Baylor College of Medicine; Orlando Health, Inc.; Virginia Commonwealth University; Trustees of Indiana University
- First posted
- Nov 26, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 1 day, up to 104 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectual outcome and brain structural integrity between these two treatments, to help families make the best treatment decision for their baby.
Conditions
- Hydrocephalus
Interventions
Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)Procedure
Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.
Ventriculoperitoneal ShuntDevice
The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bayley Scale of Infant Development-IV (Bayley-IV) Cognitive Scale scoreTime frame: 12 months post randomized surgical intervention
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Children's of Alabama
Birmingham, Alabama
Phoenix Children's Hospital
Phoenix, Arizona
Children's Hospital of Los Angeles
Los Angeles, California
18 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.